Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-11-01
coleção:	Atherosclerosis Plus
Assuntos:	Evolocumab Alirocumab PCSK9i Hypercholesterolemia familiar Cardiovascular disease Statins intolerance
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2667089521000419
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!